Class Action Lawsuit Announced for Pacira Biosciences, Inc.
Pomerantz LLP has recently filed a class action lawsuit against Pacira Biosciences, Inc. (NASDAQ: PCRX). This action involves investors who have suffered financial losses related to their investments in Pacira. If you are affected, it's crucial to contact a representative from Pomerantz for guidance on the next steps.
Understanding the Class Action
The essence of the class action centers on allegations that Pacira and certain key officers or directors may have engaged in unlawful business practices, including potential securities fraud. Such claims, if proven, could lead to significant implications for those holding shares of the company.
Deadline for Lead Plaintiff Applications
Interested investors have until a specified date to request appointment as Lead Plaintiff in this class action. Engaging in this lawsuit could be pivotal for investors aiming to recover lost funds from their investments in Pacira. A copy of the filed complaint is available for review, and investors are encouraged to familiarize themselves with its contents.
Recent Developments Affecting Pacira
Recently, Pacira faced serious challenges when a patent infringement lawsuit led to the invalidation of its '495 patent for Exparel, a non-opioid pain management option. This ruling was based on grounds of obviousness and anticipation, significantly impacting Pacira's market position and investor confidence.
Impact on Stock Performance
Following the news of the invalidation, appreciation in Pacira's stock price was swiftly reversed. The stock plunged by over 47%, indicating how sensitive the market can be to legal challenges and patent issues. For current and potential investors, such volatility highlights the importance of staying updated on the company's legal battles and financial health.
Pomerantz LLP and Its Role
Pomerantz LLP is recognized for its expertise in handling corporate, securities, and antitrust class litigation. With a history spanning over 85 years, the firm, founded by notable attorney Abraham L. Pomerantz, has consistently fought for the rights of securities fraud victims. As they take on this class action, investors can take solace in the firm's dedication to recovering damages for those affected by corporate misconduct.
Contact Information for Affected Investors
If you believe you are impacted by these developments, reach out to Danielle Peyton at Pomerantz for more information about joining the class action. Including your contact details and number of shares at the time of purchase will aid in expediting your inquiry.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit alleges that Pacira and certain officials may have engaged in securities fraud or other unlawful practices affecting shareholders.
How can affected individuals participate?
Affected investors can express their interest in joining the class action by contacting Pomerantz LLP for guidance.
What recent event affected Pacira’s stock?
A patent for Pacira's Exparel was recently invalidated, leading to a drastic decline in the stock price.
Who should I contact for more information?
Investors can reach out to Danielle Peyton at Pomerantz LLP for further information on the lawsuit and next steps.
What is Pacira Biosciences, Inc.'s stock ticker?
The stock ticker for Pacira Biosciences, Inc. is NASDAQ: PCRX.
